Ilepatril

Ilepatril

Ilepatril is a pharmaceutical compound that functions as a dual inhibitor of the enzymes neprilysin and angiotensin-converting enzyme (ACE). It is primarily investigated for its potential use in the treatment of hypertension and heart failure. By inhibiting these enzymes, Ilepatril aims to enhance the levels of natriuretic peptides while simultaneously reducing the production of angiotensin II, thereby exerting beneficial effects on cardiovascular function.

Mechanism of Action

Ilepatril works by targeting two key enzymes involved in cardiovascular regulation:

• Neprilysin: This enzyme is responsible for the breakdown of natriuretic peptides, which are hormones that help regulate blood pressure and fluid balance. By inhibiting neprilysin, Ilepatril increases the levels of these peptides, promoting vasodilation and natriuresis (excretion of sodium in urine).

• Angiotensin-Converting Enzyme (ACE): ACE plays a crucial role in the renin-angiotensin-aldosterone system (RAAS) by converting angiotensin I to angiotensin II, a potent vasoconstrictor. Inhibition of ACE by Ilepatril reduces the formation of angiotensin II, leading to vasodilation and decreased blood pressure.

The dual inhibition of neprilysin and ACE by Ilepatril results in a synergistic effect, enhancing cardiovascular protection and improving outcomes in patients with heart failure and hypertension.

Clinical Applications

Ilepatril has been studied in clinical trials for its efficacy in treating:

• Hypertension: By lowering blood pressure through dual enzyme inhibition, Ilepatril offers a novel approach to managing hypertension, especially in patients who may not respond adequately to conventional therapies.

• Heart Failure: The compound's ability to modulate the RAAS and increase natriuretic peptide levels makes it a promising candidate for improving cardiac function and reducing symptoms in heart failure patients.

Research and Development

Research on Ilepatril is ongoing, with several clinical trials evaluating its safety, efficacy, and potential side effects. The dual mechanism of action presents a unique therapeutic opportunity, but also poses challenges in balancing the effects on different physiological pathways.

Potential Side Effects

As with any pharmacological agent, Ilepatril may have side effects, including:

• Hypotension: Due to its vasodilatory effects, there is a risk of excessive lowering of blood pressure.
• Renal Impairment: Monitoring of kidney function is necessary, as alterations in renal hemodynamics can occur.
• Hyperkalemia: Elevated potassium levels may result from RAAS inhibition, necessitating regular monitoring.

Also see

• Neprilysin Inhibitors
• Angiotensin-Converting Enzyme Inhibitors
• Heart Failure Treatment
• Hypertension Management

Cardiovascular disease A-Z

Most common cardiac diseases

• Cardiac arrhythmia‎
• Cardiogenetic disorders‎
• Cardiomegaly‎
• Cardiomyopathy‎
• Cardiopulmonary resuscitation‎
• Chronic rheumatic heart diseases‎
• Congenital heart defects‎
• Heart neoplasia‎
• Ischemic heart diseases‎
• Pericardial disorders
• Syndromes affecting the heart‎
• Valvular heart disease‎

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

A

• Accelerated idioventricular rhythm
• Acute decompensated heart failure
• Arteriosclerotic heart disease
• Athletic heart syndrome
• Atrial flutter
• Atrioventricular fistula
• Cardiovascular disease in Australia
• Autoimmune heart disease

B

• Brown atrophy of the heart

C

• Ebb Cade
• Cardiac allograft vasculopathy
• Cardiac amyloidosis
• Cardiac asthma
• Cardiac tamponade
• Cardiogenic shock
• Cardiogeriatrics
• Cardiorenal syndrome
• Cardiotoxicity
• Carditis
• Coronary artery aneurysm
• Coronary artery anomaly
• Coronary artery disease
• Spontaneous coronary artery dissection
• Coronary artery ectasia
• Coronary occlusion
• Coronary steal
• Coronary thrombosis
• Coronary vasospasm
• Cœur en sabot
• Coxsackievirus-induced cardiomyopathy

D

• Duke Treadmill Score
• Duroziez's disease

E

• Eisenmenger's syndrome
• Embryocardia
• Endocardial fibroelastosis
• Eosinophilic myocarditis

H

• Heart attack
• Heart failure
• Heart failure with preserved ejection fraction
• Heart to Heart (1949 film)
• High-output heart failure
• Hyperdynamic precordium

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

I

• Idiopathic giant-cell myocarditis
• Interventricular dyssynchrony
• Intraventricular dyssynchrony
• Isolated atrial amyloidosis

K

• Keshan disease

L

• Loeffler endocarditis

M

• Mydicar
• Myocardial bridge
• Myocardial disarray
• Myocardial rupture
• Myocardial scarring
• Myocardial stunning
• Myocarditis

N

• Nonbacterial thrombotic endocarditis

O

• OLR1
• Ostial disease

P

• Papillary fibroelastoma
• Pathophysiology of heart failure
• Postpericardiotomy syndrome
• Pulmonary vein stenosis

R

• Right axis deviation
• Roemheld syndrome

S

• Saturated fat and cardiovascular disease
• SCAR-Fc
• Shone's syndrome
• Strain pattern
• Subacute bacterial endocarditis
• Sudden cardiac death of athletes

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

T

• Traumatic cardiac arrest

V

• Ventricular aneurysm
• Vibroacoustic disease
• Viral cardiomyopathy

W

• Waon therapy